Risk of cancer among commercially insured HIV-infected adults on antiretroviral therapy Journal Article

Authors: Lee, J. Y.; Dhakal, I.; Casper, C.; Noy, A.; Palefsky, J. M.; Haigentz, M.; Krown, S. E.; Ambinder, R. F.; Mitsuyasu, R. T.
Article Title: Risk of cancer among commercially insured HIV-infected adults on antiretroviral therapy
Abstract: The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLinkĀ® Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (<30, 30-39, 40-49, 50-59, and >60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized incidence ratios (SIRs) were estimated using their 95% confidence intervals (CIs). Compared to the general population, incidence rates for HIV-infected adults were elevated (SIR, 95% CI) for Kaposi sarcoma (46.08; 38.74-48.94), non-Hodgkin lymphoma (4.22; 3.63-4.45), Hodgkin lymphoma (9.83; 7.45-10.84), and anal cancer (30.54; 25.62-32.46) and lower for colorectal cancer (0.69; 0.52-0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45-0.58). Commercially insured, treated HIV-infected adults had elevated rates for infection-related cancers, but not for common non-AIDS defining cancers. Ā© 2016 Jeannette Y. Lee et al.
Journal Title: Journal of Cancer Epidemiology
Volume: 2016
ISSN: 1687-8558
Publisher: Hindawi Publishing Corporation  
Date Published: 2016-01-01
Start Page: 2138259
Language: English
DOI: 10.1155/2016/2138259
PROVIDER: scopus
PMCID: PMC5110893
PUBMED: 27882054
Notes: Article -- Export Date: 3 January 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Ariela Noy
    210 Noy
Related MSK Work